hydroxyurea has been researched along with Angiitis in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a 45-year-old male with chronic myelogenous leukemia (CML) who experienced skin ulcers of the left lateral malleolus and dorsum of both feet." | 5.30 | [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia]. ( Irimajiri, J; Ito, T; Kanazawa, A; Kawahara, Y; Kudo, H; Ohkubo, H; Tomiyama, J; Uchino, S; Yano, K, 1997) |
| "An electronic search encompassing MEDLINE, PubMed, Cochrane Library, and Scopus was completed using the following search terms: rheumatoid arthritis; systemic sclerosis; systemic lupus erythematosus; antineutrophil cytoplasmic antibody-associated vasculitis; mixed connective tissue disease; antiphospholipid syndrome; pyoderma gangrenosum; thromboangiitis obliterans; cryoglobulinemia; hydroxyurea; sickle cell; atrophie blanche; livedoid vasculitis; cholesterol emboli; calciphylaxis; antiphospholipid antibodies; prothrombotic; combined with the terms: chronic wound and leg ulcer." | 4.95 | Vasculitic and autoimmune wounds. ( Angra, D; McNish, S; Rahimi, H; Shanmugam, VK, 2017) |
| "We report a 45-year-old male with chronic myelogenous leukemia (CML) who experienced skin ulcers of the left lateral malleolus and dorsum of both feet." | 1.30 | [Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia]. ( Irimajiri, J; Ito, T; Kanazawa, A; Kawahara, Y; Kudo, H; Ohkubo, H; Tomiyama, J; Uchino, S; Yano, K, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaztanaga, J | 1 |
| Farkouh, M | 1 |
| Rudd, JH | 1 |
| Brotz, TM | 1 |
| Rosenbaum, D | 1 |
| Mani, V | 1 |
| Kerwin, TC | 1 |
| Taub, R | 1 |
| Tardif, JC | 1 |
| Tawakol, A | 1 |
| Fayad, ZA | 1 |
| Shanmugam, VK | 1 |
| Angra, D | 1 |
| Rahimi, H | 1 |
| McNish, S | 1 |
| Hendrick, A | 1 |
| Tomiyama, J | 1 |
| Yano, K | 1 |
| Uchino, S | 1 |
| Ito, T | 1 |
| Kudo, H | 1 |
| Irimajiri, J | 1 |
| Ohkubo, H | 1 |
| Kanazawa, A | 1 |
| Kawahara, Y | 1 |
| Fischer, TJ | 1 |
| Daugherty, C | 1 |
| Gushurst, C | 1 |
| Kephart, GM | 1 |
| Gleich, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event[NCT00552188] | Phase 2 | 52 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the target (plaque) to background (blood) ratio (TBR) from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18fluorodeoxy glucose (FDG) uptake measured with PET in patients with acute coronary syndrome and vascular inflammation after 24 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 24 Weeks
| Intervention | TBR (Least Squares Mean) |
|---|---|
| VIA-2291 | -0.01 |
| Placebo | -0.06 |
To evaluate the effect of VIA-2291 100 mg relative to placebo on the change from baseline in the TBR from an index vessel (either right carotid, left carotid or ascending aorta) based on the standardized 18FDG uptake measured with PET in patients after 6 weeks of daily dosing. (NCT00552188)
Timeframe: Baseline and 6 Weeks
| Intervention | TBR (Least Squares Mean) |
|---|---|
| VIA-2291 | 0.01 |
| Placebo | -0.07 |
1 review available for hydroxyurea and Angiitis
| Article | Year |
|---|---|
Vasculitic and autoimmune wounds.
Topics: Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Sy | 2017 |
1 trial available for hydroxyurea and Angiitis
| Article | Year |
|---|---|
A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aortitis; Aortography; Canada; Carotid Artery Diseases; Double-Blind | 2015 |
3 other studies available for hydroxyurea and Angiitis
| Article | Year |
|---|---|
Psychosis during interferon in eosinophilic leukaemia.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 1994 |
[Bilateral leg ulcers with pathologic evidence of small vessel vasculitis by skin biopsy during hydroxyurea therapy of chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Biopsy; Humans; Hydroxyurea; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-A | 1997 |
Systemic vasculitis associated with eosinophilia and marked degranulation of tissue eosinophils.
Topics: Blood Proteins; Child; Diagnosis, Differential; Eosinophil Granule Proteins; Eosinophilia; Eosinophi | 1988 |